Mechnikov Sa

What Mechnikov Sa does

Mechnikov Sa (legally Instituto Latinoamericano de Biotecnologia MECHNIKOV, S.A.) is a privately held Nicaraguan biotechnology company incorporated in February 2015 as a Russia-Nicaragua joint venture that grew out of an April 2014 memorandum between Russia's St. Petersburg Institute of Vaccines and Sera (IICVSSP) and Nicaragua's Social Security Institute (INSS). The company operates a single integrated manufacturing facility in Managua — inaugurated in October 2016 and the only biotech plant in Central America built to WHO requirements and GMP standards — with capacity to produce up to 30 million doses of vaccines and biological medicines per season. The facility received GMP certification from CECMED (Cuba) in March 2019, began commercial production in April 2019, and has since supplied over 28 million doses across the Latin America and Caribbean (LAC) region. Mechnikov employs 58 people at its Managua headquarters.

The company develops and manufactures immunobiological products using split virion inactivation technology combined with a proprietary high-purification process that achieves ovalbumin content approximately 1,000 times lower than comparable products, reducing the risk of allergic reactions. Core marketed products include FLU-M® (a trivalent inactivated influenza vaccine that became the first Central American flu vaccine to receive WHO prequalification in January 2025), FLU-M® Tetra (a quadrivalent influenza vaccine), Convacell® (a recombinant subunit COVID-19 vaccine), and the Inactivated Split Influenza Vaccine. Pipeline products NEUMO-M® 13 (a 13-valent pneumococcal conjugate vaccine) and EPOCIM® (recombinant human erythropoietin in 2,000/4,000/10,000 IU presentations) are in preparation. The modular manufacturing platform supports a diversified portfolio and enables contract manufacturing (maquila) services for third-party pharmaceutical clients.

Revenue is generated through three streams: wholesale vaccine product sales, contract manufacturing services for immunobiological preparations under GMP, and technology transfer and professional training. Distribution runs almost entirely through B2G and institutional channels — primarily UNICEF, PAHO, and national ministries of health across the LAC region — with no publicly disclosed pricing. The company maintains a broad partner network spanning Russian technology providers (IICVSSP, FMBA institutes, Institute of Immunology), Cuban regulatory and biotech partners (CECMED, BioCubaFarma, CIM), Chinese manufacturers (Sinopharm, Biokangtai, Innovax), and Indian biopharma (MJ Biopharma), supported by an annual International Pharmaceutical Congress Russia-Nicaragua held since 2014.

Name

Mechnikov Sa

Legal name

Instituto Latinoamericano de Biotecnologia MECHNIKOV, S.A.

Website

https://mechnikov.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

51–100 employees

Short description

Instituto Latinoamericano de Biotecnologia MECHNIKOV, S.A. is a Nicaragua-based biotechnology company operating the only GMP-certified sterile immunobiological facility in Central America, producing WHO-prequalified influenza and other vaccines for Latin American and Caribbean government health agencies, UNICEF, and PAHO.

Ownership category

akta.pro rank

Product category

Vaccine Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro industry

PRIMARYHLAIAEAD

Seasonal & Endemic Vaccines (e.g., Influenza)

Healthcare & Life Sciences/Pharmaceuticals/Vaccines

SECONDARYHLAIAEAK

Vaccine Cold Chain, Storage & Distribution

Healthcare & Life Sciences/Pharmaceuticals/Vaccines

SECONDARYHLAIAEAN

Vaccine Procurement, Tendering & Immunization Supply Programs

Healthcare & Life Sciences/Pharmaceuticals/Vaccines

SECONDARYBPADAIAB

Immunization & Vaccine Delivery Programs

Business & Public Services/International Organizations & Development/Global Health & Population Programs

SECONDARYTLAIAIAD

Vaccine & Public Health Immunization Cold Chain Logistics

Transportation & Logistics/Third-Party & Fourth-Party Logistics (3PL/4PL) / Contract Logistics/Cold Chain 3PL (Temperature-Controlled Logistics)

Keywords

• Vaccine manufacturing
• Influenza vaccines
• Biotechnology manufacturing
• Immunobiological products
• Contract manufacturing

Headquarters

HQ city

Managua

HQ country

Nicaragua

HQ region

Latin America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Personnel, Supply Chain, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Vaccine Product Sales: Production and wholesale distribution of immunobiological products including FLU-M, FLU-M Tetra, Inactivated Split Influenza Vaccine, Convacell COVID-19 vaccine, and upcoming products like NEUMO-M 13 and EPOCIM erythropoietin.
2. Contract Manufacturing (Maquila Services): Fill-and-finish services for immunobiological preparations under strict GMP compliance. Clients benefit from savings on equipment, facilities, laboratory work, training, and personnel costs.
3. Technology Transfer Services: Transfer of experience and knowledge, professional development and training of highly qualified personnel for biotechnology manufacturing.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels5 records

Core offering

Mechnikov Sa develops and manufactures vaccines and immunobiological products, including inactivated split influenza vaccines (FLU-M, FLU-M Tetra), COVID-19 vaccine (Convacell), pneumococcal vaccine (NEUMO-M 13) and erythropoietin (EPOCIM). The Managua-based plant operates as a joint Russia-Nicaragua venture and offers contract manufacturing (maquila) services to third parties, with annual capacity of up to 30 million doses per season.

Product overview

Mechnikov Sa (Instituto Latinoamericano de Biotecnología MECHNIKOV, S.A.) is a modern high-tech biotechnology platform in Managua, Nicaragua, dedicated to the development and manufacture of immunobiological products. The company operates as a single integrated facility with a diversified vaccine and biological product portfolio, including three influenza vaccines (FLU-M® trivalent, FLU-M® Tetra tetravalent, and Inactivated Split Influenza Vaccine), the COVID-19 vaccine Convacell®, the pneumococcal conjugate vaccine NEUMO-M® 13, and the erythropoietin product EPOCIM® in multiple strengths. The institute also offers contract manufacturing (maquila) services for other immunobiological preparations. Production capacity reaches up to 30 million doses of influenza vaccine per season. As the only biotech plant in Central America built to WHO requirements and GMP standards, the institute serves the Latin American and Caribbean region, having supplied over 28 million doses since founding in 2019.

Differentiator

Problem solved

Functional benefit

Brands

• FLU-M: Influenza vaccine (split virion, inactivated) - WHO prequalified trivalent flu vaccine
• FLU-M Tetra
• Convacell
• NEUMO-M 13
• EPOCIM

Products and services

• FLU-M

Quantifiable outcome

• Ovalbumin content reduced to 1000x lower than similar products, minimizing allergic reactions
• +3 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Ten partnerships are on record, tiered flagship, core and minor.

• St. Petersburg Institute of Vaccines and Sera (IICVSSP/SPbSRIVS)flagshipStrategic or Co-development Partner · 27 April 2014Collaboration for influenza vaccine technology transfer, production, and manufacturing. The Russian institute serves as the technology provider and primary partner for the Mechnikov facility in Nicaragua.
• UNAN-ManaguacoreStrategic or Co-development PartnerEducational partnership for professional development, workforce training, and integration of industry with academia. Includes joint events, scientific workshops, and the BioNICA program for training Nicaraguan students.
• UNICEFcoreChannel Partner/ Reseller/ DistributorInternational procurement agency for vaccines; recommended for purchase by UNICEF following WHO prequalification of FLU-M vaccine.
• Pan American Health Organization (PAHO)coreChannel Partner/ Reseller/ DistributorRegional health organization that recommends and facilitates procurement of FLU-M vaccine for member countries.
• CECMED (Cuba)coreStrategic or Co-development PartnerNational regulatory authority of Cuba serving as reference NRA for the region. Conducted GMP inspections and issued certifications for Mechnikov facilities.
• INSS (Nicaragua)coreStrategic or Co-development PartnerNicaragua Social Security Institute; signed original memorandum in 2014 and participates in congress presidium.
• DCVMN (Developing Country Vaccine Manufacturers Network)minorStrategic or Co-development PartnerInternational network of vaccine manufacturers from developing countries.
• Laboratorios RAMOS (Nicaragua)minorChannel Partner/ Reseller/ DistributorNicaraguan pharmaceutical laboratory listed as partner.
• Rossotrudnichestvo AgencyminorStrategic or Co-development PartnerRussian agency for international cooperation, represented in Nicaragua by Sofia Kharbikh.
• MINSA (Nicaragua)coreStrategic or Co-development PartnerMinistry of Health of Nicaragua participates in congress presidium and coordinates on regulatory affairs.

Scale indicators6 records

Recent moves5 records

Expansion highlights5 records

Others

• Pan American Health Organization (PAHO) Revolving Fund: Regional procurement agency channeling multi-country vaccine demand to WHO-prequalified manufacturers like Mechnikov. Listed as a partner/customer and represents the primary distribution channel that defines addressable volume for DCVMN manufacturers in the region.

Broad incumbents

• Sinopharm: China's largest state-owned pharma group with extensive WHO-prequalified vaccine portfolio and global UNICEF/PAHO supply presence. Comparable as a DCVMN super-incumbent scaling in the same WHO-prequalified, multi-SKU influenza/COVID franchise with a maquila-like technology-transfer model.

Regional players

• Laboratorios RAMOS: Nicaraguan pharmaceutical laboratory listed as a Mechnikov distribution partner with operations in the same local market. Comparable as a Nicaragua-based pharmaceutical company with overlapping product and customer base.

Direct peers

• BioCubaFarma / Instituto Finlay de Vacunas: Cuba's national biotech consortium with WHO-prequalified vaccines serving Latin American and developing country markets via PAHO Revolving Fund. Directly comparable as a state-backed DCVMN manufacturer serving the same UNICEF/PAHO procurement channels and LAC public health agencies.
• Instituto Butantan: Brazil's largest immunobiological producer with WHO-prequalified influenza vaccines supplied to PAHO Revolving Fund. Comparable in product portfolio, regulatory pathway, and DCVMN-aligned regional distribution to LAC.
• St. Petersburg Institute of Vaccines and Sera (SPbSRIVS/IICVSSP): Russian state-owned vaccine institute and Mechnikov's foundational technology partner, providing the FLU-M split-virion platform and process technology that underpins manufacturing in Nicaragua. Directly comparable in product portfolio (split influenza), GMP operations, and target regulatory pathway.
• Bio-Manguinhos / Fiocruz: Brazil's federal public vaccine manufacturer operating under the MoH, producing WHO-prequalified yellow fever and influenza vaccines for PAHO procurement across LAC. Directly comparable in role as a public-sector-aligned DCVMN producer competing for the same regional tenders.
• BioKangtai: China-based vaccine manufacturer listed as a partner of Mechnikov and competitor for WHO prequalified influenza and other vaccine tenders in emerging markets. Comparable as a DCVMN influenza producer pursuing the same UNICEF/PAHO channels.

Emerging players

• MJ Biopharma (M.J. Group): India-based vaccine and biopharma manufacturer listed as a Mechnikov partner, producing vaccines for global health tenders. Comparable as an emerging-market DCVMN manufacturer competing for WHO prequalified franchise opportunities.
• INNOVAX (Wantai): Chinese biotech with WHO-prequalified HPV and other vaccines, expanding into the same DCVMN export channels. Comparable as an emerging DCVMN manufacturer pursuing WHO prequalification and global health tenders.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/ilabmechnikov
• LinkedInlinkedin.com/company/mechnikov-sa

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mechnikov Sa